Acquisition of MotionHall reinforces strategy to lead
market-specific solutions, including workflows and expert services
fuelled by industry vertical AI
LONDON, March 21, 2024 /PRNewswire/ -- Clarivate Plc
(NYSE:CLVT) a leading global provider of transformative
intelligence, has announced an agreement to acquire the substantial
majority of assets of MotionHall, a Silicon Valley technology
start-up company serving the life sciences with industry vertical
artificial intelligence (AI) solutions. The asset purchase serves
as a key component of the Clarivate™ Life Sciences & Healthcare
strategy to deliver transformative intelligence through the
application of generative AI (GenAI) and proprietary industry
vertical AI solutions. Clarivate provides people and organizations
with transformative intelligence they can trust, propelling human
ingenuity into our world's greatest breakthroughs.
The acquisition of the full intellectual property, clients and
team from MotionHall enables acceleration of multiple roadmaps,
including targeted enhancements to Clarivate Cortellis™, market
assessments, as well as a new Business Development & Licensing
Enterprise Workbench.
Henry Levy, President, Life
Sciences & Healthcare, Clarivate said: "As part of our
strategy, Clarivate will enhance existing products and introduce
novel solutions utilizing AI, to streamline clients' workflows and
accelerate speed to insight and action. Concurrent with this
transaction, the team from MotionHall has joined Clarivate to
progress our on-going commitment to provide exceptional value for
our clients across the entire drug, device and medical technology
lifecycle."
Rachael Craig, SVP and
Managing Director, Life Sciences & Healthcare Strategy
Products, Clarivate, said: "Clarivate is well positioned to
become a leading industry vertical artificial intelligence (AI)
player. Your healthier tomorrow is being built through the
successful combination of deep life sciences industry expertise and
mastery of frontier AI capabilities. Clients who choose Clarivate
as we advance industry vertical AI together, will have access to
this frontier, becoming better equipped to deliver outcomes for
their company and patients that meet today's complex
challenges."
In the near-term, Clarivate will leverage MotionHall IP to
further enhance Cortellis search, as well as scope of data quality
and coverage.
To learn more about Clarivate Portfolio Strategy & Business
Development Solutions, visit,
https://clarivate.com/industries/life-sciences-and-healthcare/.
About Clarivate
Clarivate™ is a leading global provider of transformative
intelligence. We offer enriched data, insights & analytics,
workflow solutions and expert services in the areas of Academia
& Government, Intellectual Property and Life Sciences &
Healthcare. For more information, please
visit www.clarivate.com
Cautionary Note Regarding Forward-Looking Statements
This release contains "forward-looking statements" as defined in
the Private Securities Litigation Reform Act of 1995.
Forward-looking statements are neither historical facts nor
assurances of future performance. Instead, they are based only on
management's current beliefs, expectations, and assumptions
regarding the future of our business, future plans and strategies,
projections, anticipated events and trends, the economy, and other
future conditions. Because forward-looking statements relate to the
future, they are difficult to predict and many of which are outside
of our control. Important factors that could cause our actual
results to differ materially from those indicated in the
forward-looking statements are discussed under the caption "Risk
Factors" in our Annual Report on Form 10-K, along with our other
filings with the U.S. Securities and Exchange Commission ("SEC").
However, those factors should not be considered to be a complete
statement of all potential risks and uncertainties. Additional
risks and uncertainties not known to us or that we currently deem
immaterial may also impair our business operations. Forward-looking
statements are based only on information currently available to our
management and speak only as of the date of this release. We do not
assume any obligation to publicly provide revisions or updates to
any forward-looking statements, whether as a result of new
information, future developments or otherwise, except as otherwise
required by securities and other applicable laws. Please consult
our public filings with the SEC or on our website at
www.clarivate.com.
Media Contact:
Catherine Daniel, Director, External
Communications, Life Sciences & Healthcare
newsroom@clarivate.com
Investor Relations Contact:
Mark Donohue, Head of Investor
Relations
Mark.donohue@clarivate.com
Logo -
https://mma.prnewswire.com/media/1159266/Clarivate_Logo.jpg
View original
content:https://www.prnewswire.co.uk/news-releases/clarivate-acquires-ai-start-up-to-accelerate-strategy-and-business-development-success-for-life-sciences--healthcare-clients-302095057.html